Erdaftinib is a targeted therapy approved for the treatment of adults with locally advanced or metastatic urothelial carcinoma (bladder cancer) who have specific FGFR2 or FGFR3 gene mutations. Erdaftinib works by blocking FGFR proteins (fibroblast growth factor receptors), which play a role in cancer cell growth and survival. By inhibiting these proteins, Erdaftinib can slow down tumor growth in patients whose cancer has these genetic changes.

Benefits of Erdaftinib Tablets

🔹 Precision Medicine: Specifically targets FGFR-mutated bladder cancer.
🔹 Oral Convenience: Tablets can be taken at home, improving patient convenience.
🔹 First-in-Class Therapy: The first approved FGFR-targeted drug for bladder cancer.
🔹 Effective After Chemotherapy: Offers a treatment option when standard chemotherapy stops working.

Possible Side Effects of Erdaftinib Tablets

While Erdaftinib offers promising benefits, it may also cause some side effects, including:

• Dry mouth
• Nail changes
• Eye problems (blurred vision, dry eyes)
• Mouth sores
• Fatigue
• Diarrhea
• High phosphate levels (hyperphosphatemia)

Patients should undergo regular eye exams during treatment due to potential vision changes.

Disclaimer

RxLane provides information for educational purposes only. All trademarks, brands, and service marks are the property of their respective owners. RxLane does not offer medical advice. Please consult your doctor for appropriate diagnosis and treatment. This content is intended for wholesalers, doctors, hospitals, clinics, pharmacies, and medical institutions.